Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -52.8%. (2009–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2576 | $16M | $50M | $37M | $120M | $72M | $75M | $69M | $70M | $62M | $62M |
| Enterprise Value | $54M | $70M | $100M | $86M | $163M | $111M | $96M | $111M | $108M | $90M | $103M |
| P/E Ratio → | -0.00 | — | 3.76 | — | — | — | — | — | — | 207.10 | — |
| P/S Ratio | 0.00 | 0.26 | 0.68 | 0.52 | 1.42 | 0.91 | 0.69 | 1.08 | 0.93 | 0.64 | 0.76 |
| P/B Ratio | 0.00 | 0.35 | 0.72 | 0.72 | 1.61 | 0.89 | 0.75 | 0.85 | 1.14 | 0.91 | 1.19 |
| P/FCF | — | — | — | — | — | — | 3.68 | — | — | 15.08 | 6.50 |
| P/OCF | — | — | — | — | — | — | 3.55 | — | — | 9.21 | 5.56 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.15 | 1.35 | 1.21 | 1.94 | 1.40 | 0.88 | 1.74 | 1.43 | 0.94 | 1.27 |
| EV / EBITDA | — | — | — | — | — | — | 6.17 | 249.50 | 117.64 | 17.19 | 22.56 |
| EV / EBIT | — | — | 4.72 | — | — | — | — | — | — | 22.77 | 136.20 |
| EV / FCF | — | — | — | — | — | — | 4.68 | — | — | 21.91 | 10.82 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.2% | 26.2% | 19.8% | 8.9% | 16.3% | 18.8% | 37.1% | 23.0% | 21.4% | 19.1% | 20.4% |
| Operating Margin | -29.3% | -29.3% | -24.4% | -46.0% | -24.1% | -21.1% | 10.4% | -4.7% | -3.2% | 2.1% | 2.9% |
| Net Profit Margin | -49.7% | -49.7% | 19.6% | -50.9% | -22.7% | -24.8% | -8.5% | -7.4% | -15.7% | 0.4% | -3.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.8% | -52.8% | 24.0% | -57.7% | -24.5% | -21.8% | -10.3% | -6.6% | -18.3% | 0.6% | -6.1% |
| ROA | -22.0% | -22.0% | 10.1% | -25.5% | -12.4% | -13.1% | -6.6% | -3.7% | -9.7% | 0.3% | -3.0% |
| ROIC | -12.0% | -12.0% | -12.1% | -22.5% | -12.8% | -10.5% | 7.0% | -2.0% | -1.9% | 1.6% | 2.2% |
| ROCE | -26.8% | -26.8% | -21.6% | -37.3% | -20.9% | -15.6% | 11.0% | -3.7% | -3.2% | 2.5% | 3.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.21 | 1.21 | 0.82 | 0.99 | 0.63 | 0.53 | 0.24 | 0.56 | 0.63 | 0.52 | 0.86 |
| Debt / EBITDA | — | — | — | — | — | — | 1.54 | 103.46 | 42.30 | 6.68 | 9.79 |
| Net Debt / Equity | — | 1.20 | 0.72 | 0.95 | 0.59 | 0.48 | 0.21 | 0.51 | 0.62 | 0.41 | 0.79 |
| Net Debt / EBITDA | — | — | — | — | — | — | 1.32 | 93.76 | 41.49 | 5.36 | 9.02 |
| Debt / FCF | — | — | — | — | — | — | 1.00 | — | — | 6.83 | 4.33 |
| Interest Coverage | -2.61 | -2.61 | 3.42 | -10.15 | -5.44 | -6.66 | -1.94 | -1.25 | -0.68 | 0.66 | 0.16 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | 0.92 | 1.18 | 1.60 | 1.44 | 1.68 | 2.70 | 1.88 | 1.11 | 1.39 | 1.34 |
| Quick Ratio | 0.36 | 0.36 | 0.55 | 0.47 | 0.40 | 0.47 | 0.60 | 0.46 | 0.49 | 0.86 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.05 | 0.04 | 0.06 | 0.08 | 0.10 | 0.10 | 0.01 | 0.17 | 0.08 |
| Asset Turnover | — | 0.50 | 0.48 | 0.53 | 0.55 | 0.51 | 0.75 | 0.47 | 0.64 | 0.76 | 0.66 |
| Inventory Turnover | 1.17 | 1.17 | 1.31 | 1.19 | 1.11 | 1.01 | 0.97 | 0.82 | 1.88 | 3.55 | 2.53 |
| Days Sales Outstanding | — | 126.00 | 156.23 | 97.45 | 84.20 | 87.25 | 44.51 | 78.95 | 112.54 | 104.96 | 120.13 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 26.6% | — | — | — | — | — | — | 0.5% | — |
| FCF Yield | — | — | — | — | — | — | 27.2% | — | — | 6.6% | 15.4% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $885902 | $746815 | $666669 |
Imminent liquidity and solvency
As reported in recent financial statements, the company's operating margin of -29.26% highlights a structural inability to cover fixed costs, while gross margins remain volatile, fluctuating between 7.2% and 37.7% over the last ten quarters due to inventory write-downs and competitive pricing pressures in the seed market.
The wide variance in gross margins suggests that the company is highly susceptible to inventory impairment, which frequently masks the underlying profitability of its core seed sales. Investors should interpret the negative operating margins as a clear indicator that the current revenue scale is insufficient to support the firm's R&D and administrative overhead.
Based on historical data, the company's ROIC has remained consistently negative, reaching -1.0% in 2025Q3, which indicates that the firm is failing to generate adequate returns on its invested capital compared to the cost of funding its operations and maintaining its genetic asset library.
The persistent decay in ROIC suggests that past capital allocation decisions have not yielded the expected economies of scale or competitive advantages. This trend warrants further investigation into whether the company's proprietary germplasm can ever be monetized effectively enough to offset the heavy capital intensity of the agricultural seed business.
According to quarterly filings, the cash conversion cycle has been extremely volatile, peaking at 899 days in 2024Q2, which underscores the significant difficulty in managing inventory and collecting receivables within the seasonal and geographically dispersed nature of the company's international forage seed operations.
The exceptionally high days inventory outstanding (DIO) suggests that the company is holding significant amounts of biological assets that may be at risk of degradation or obsolescence. This inefficiency in working capital management directly contributes to the firm's liquidity stress, as cash remains trapped in inventory for extended periods.
As indicated by the most recent quarterly data, the company's cash and equivalents have dwindled to a precarious $294,014, a level that appears insufficient to sustain ongoing operations or meet seasonal working capital requirements without the potential for further dilutive financing or asset divestitures.
The current ratio hovering near 1.00, combined with a quick ratio of 0.47, suggests that the company lacks a sufficient buffer to absorb even minor operational shocks. Investors should monitor the firm's ability to secure additional funding, as the current liquidity position appears highly vulnerable to any disruption in the planting cycle.
Market participants often misapply price-to-sales multiples to this business model, which obscures the reality that the company's revenue is currently generated at a negative operating margin, rendering traditional top-line valuation metrics largely irrelevant for assessing the firm's true intrinsic value or its path to profitability.
Instead of relying on P/S ratios, analysts should focus on the liquidation value of the company's genetic assets and the cash burn rate relative to its remaining liquidity. The focus on revenue growth ignores the fundamental issue that the current business model is not yet self-sustaining, making cash-flow-based metrics far more critical.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SANW stock.
S&W Seed Company's current P/E ratio is -0.0x. The historical average is 38.6x.
S&W Seed Company's return on equity (ROE) is -52.8%. The historical average is -10.1%.
Based on historical data, S&W Seed Company is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
S&W Seed Company has 26.2% gross margin and -29.3% operating margin.